Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.71 |
| ▸ | RXRA | P19793 | 2/20 | 0.58 |
| ▸ | RXRB | P28702 | 2/20 | 0.58 |
| ▸ | CD74 | P04233 | 1/20 | 0.56 |
| ▸ | MIF | P14174 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.54 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.53 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.53 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | DHODH | Q02127 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | PRKCI | P41743 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29627221 | 1.00 | KMO (0.71) | KMORXRARXRBCD74MIF | |
| Isophthalic Acid SCHEMBL1648911 | 0.92 | KMO (0.59) | KMOCD74MIFGAANAPRT | |
| Hydrochloric Acid SCHEMBL28532360 | 0.90 | KMO (0.59) | KMORXRARXRBCD74MIF | |
| SCHEMBL437537 | 0.88 | KMO (0.91) | KMORXRARXRBCD74MIF | |
| SCHEMBL27623946 | 0.86 | MEN1 (0.55) | KMONOTUMAURKAHDAC8PRKCI | |
| Benzoic Acid SCHEMBL29139198 | 0.86 | NAPRT (0.67) | KMOGAANAPRTNOTUM | |
| SCHEMBL30436085 | 0.86 | KMO (0.95) | KMORXRARXRBLMNAGAA | |
| SCHEMBL29577419 | 0.86 | KMO (0.87) | KMORXRARXRBLMNAGAA | |
| SCHEMBL31752544 | 0.86 | KMO (0.95) | KMORXRARXRBLMNAGAA | |
| SCHEMBL250880 | 0.86 | KMO (0.95) | KMORXRARXRBLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118184679-A | Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material | 中国石油天然气股份有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-116180236-A | Millimeter-level thorium cluster compound monocrystal, synthesis method thereof and application thereof in radiation detection and protection | 西安交通大学 | 2023-05-30 | — | — | CN | claimed |
| CN-108299478-A | A kind of cadmium Base Metal organic framework materials and its preparation method and application | 华南师范大学 | 2018-07-20 | — | — | CN | claimed |
| CN-116180236-B | Millimeter-level thorium cluster compound monocrystal, synthesis method thereof and application thereof in radiation detection and protection | 西安交通大学 | 2026-02-10 | — | — | CN | disclosed |
| US-20260027106-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2026-01-29 | — | — | US | disclosed |
| US-12534452-B2 | N-(1H-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient | KAINOS MEDICINE, INC. (KR) | 2026-01-27 | — | — | US | disclosed |
| EP-4603488-A1 | NOVEL INDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | Korea University Research and Business Foundation (KR) | 2025-08-20 | — | — | EP | disclosed |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-08-05 | — | — | US | disclosed |
| EP-4157844-B1 | 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER | CENTRE NAT RECH SCIENT (FR) | 2024-07-10 | — | — | EP | disclosed |
| CN-118184679-A | Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material | 中国石油天然气股份有限公司 | 2024-06-14 | — | — | CN | disclosed |
| WO-2024080780-A1 | NOVEL INDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | 고려대학교 산학협력단 | 2024-04-18 | — | — | WO | disclosed |
| WO-2009099736-A2 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197863-A1 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| CN-101405277-A | Dicarbonylic compounds with antibacterial activity | SALVAT LAB SA (ES) | 2009-04-08 | — | — | CN | disclosed |
| US-20070197597-A1 | Process for the preparation of tryptase inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
| US-6855717-B2 | Tetrahydroisoquinoline derivatives as modulators of dopamine D3 receptors | SMITHKLINE BEECHAM, PLC (GB) | 2005-02-15 | — | — | US | disclosed |
| US-20030191314-A1 | Tetrahydroisoquinoline derivatives as modulators of dopamine D3 receptors | SMITHKLINE BEECHAM, P.L.C. | 2003-10-09 | — | — | US | disclosed |
| EP-1086095-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2002-10-23 | — | — | EP | disclosed |
| EP-1086095-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999064412-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027106-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | KMO 1505/4885RXRA 553/4885RXRB 297/4885 |
| US-20030191314-A1 | Tetrahydroisoquinoline derivatives as modulators of dopamine D3 receptors | OPRD1, HTR3C, DRD3 | KMO 582/4885RXRA 1267/4885RXRB 860/4885 |
| US-20090197863-A1 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP2, PARP11 | KMO 985/4885RXRA 917/4885RXRB 1078/4885 |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | MERTK, RET, ERBB2 | KMO 2022/4885RXRA 670/4885RXRB 654/4885 |
| US-12534452-B2 | N-(1H-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient | IRAK4, IRAK1, IRAK2 | KMO 1461/4885RXRA 443/4885RXRB 492/4885 |
| US-20070197597-A1 | Process for the preparation of tryptase inhibitors | CMA1, TPSAB1, TPSB2 | KMO 118/4885RXRA 4883/4885RXRB 4882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.